Clene INC Form 4 insider transactions

Clene Inc.'s CFO, Morgan R. Brown, was granted 10,000 stock options under the company's 2020 Stock Plan, vesting monthly over one year.

Clene Inc.'s President and CEO, Robert Dee Etherington, was granted 10,000 stock options at an exercise price of $6.32 per share, vesting immediately.

Clene Inc.'s Chief Financial Officer, Morgan R. Brown, was granted 10,000 stock options with an exercise price of $6.32 per share, vesting immediately.

Clene Inc.'s Chief Science Officer, Mark Mortenson, received a grant of 10,000 stock options with an exercise price of $6.32 per share, vesting immediately.

General Resonance LLC, a 10% owner and director of Clene Inc., reported the sale of 3,401 common shares at $5.34 per share with a transaction date of August 21, 2025.

Clene Inc. Director Vallerie McLaughlin was granted 4,092 stock options vesting immediately at an exercise price of $3.60 per share.

Clene Inc. Director David J. Matlin was granted 7,255 stock options at an exercise price of $3.60 per share, vesting immediately.

Clene Inc. Director Matthew Kiernan was granted 3,720 stock options at an exercise price of $3.60 per share, vesting immediately.

Clene Inc. Director Alison Mosca was granted 5,674 stock options at an exercise price of $3.60 per share, vesting immediately.

Clene Inc. Director Shalom Jacobovitz was granted 5,534 stock options at an exercise price of $3.60 per share, vesting immediately.

Clene Inc. Director Jonathon Gay was granted 4,790 stock options with an immediate vesting schedule under the company's 2020 Stock Plan.

Clene Inc. Director Arjun Desai was granted 4,278 stock options with an exercise price of $3.60 per share, vesting immediately.

Clene Inc. Director Reed N. Wilcox was granted 3,720 stock options at an exercise price of $3.60 per share, vesting immediately.

General Resonance LLC, a 10% owner and director of Clene Inc., reported the sale of 600 shares of common stock at a price of $4.04 per share on June 4, 2025.

General Resonance LLC, a director and 10% owner of Clene Inc., has filed a Form 4 indicating a pre-planned sale of 600 shares of common stock at $4.121 per share, effective June 2, 2025.

General Resonance LLC, a 10% owner and director of Clene Inc., reported the sale of 410 shares of common stock at $2.80 per share, effective May 30, 2025.

General Resonance LLC, a 10% owner and director of Clene Inc., reported the sale of 410 shares of common stock at $2.73 per share, reducing its direct beneficial ownership to 709,602 shares.

General Resonance LLC, a 10% owner and director of Clene Inc., reported the sale of 420 shares of common stock at $2.595 per share, executed under a Rule 10b5-1 trading plan.

General Resonance LLC, a 10% owner and director of Clene Inc. (CLNN), has reported a pre-planned sale of 420 shares of common stock under a Rule 10b5-1 trading plan.

Clene Inc. Director Matthew Kiernan was granted a total of 6,736 stock options with an exercise price of $2.45 per share, with varying vesting schedules, as disclosed in a recent SEC Form 4 filing.

Clene Inc. Director Arjun JJ Desai was granted a total of 7,521 stock options on May 22, 2025, under the company's Amended 2020 Stock Plan, with an exercise price of $2.45 per share.

Clene Inc. Director and 10% Owner David J. Matlin reported the acquisition of 11,709 stock options in the company, granted under the Amended 2020 Stock Plan.

Clene Inc. Director Jonathon Gay was granted 8,241 stock options at an exercise price of $2.45 per share, with varying vesting schedules, as disclosed in a recent SEC Form 4 filing.

Clene Inc. Director Shalom Jacobovitz was granted 9,288 stock options with an exercise price of $2.45 per share on May 22, 2025, under the company's Amended 2020 Stock Plan.

Clene Inc. Director Alison Mosca has reported the acquisition of 9,484 stock options, with varying vesting schedules, under the company's Amended 2020 Stock Plan.

Clene Inc. Director Vallerie McLaughlin was granted a total of 7,259 stock options with an exercise price of $2.45 per share on May 22, 2025, under the company's Amended 2020 Stock Plan.

Clene Inc. Director Reed N. Wilcox was granted stock options for a total of 6,736 shares of common stock at an exercise price of $2.45 per share under the company's Amended 2020 Stock Plan.

General Resonance LLC, a 10% owner of Clene Inc., sold shares of common stock on March 18 and 19, 2025.

Director Reed N. Wilcox reports acquisition of stock options in Clene Inc.

Director Alison Mosca reports acquisition of stock options in Clene Inc. under the company's Amended 2020 Stock Plan.